What Are Zombie Cells?
Deep inside your tissues, a growing population of cells has stopped dividing but refuses to die. These senescent cells — sometimes called "zombie cells" — are alive, metabolically active, and profoundly toxic to their neighbors. They accumulate with age, and mounting evidence suggests they are a major driver of age-related disease and decline.
Cellular senescence was first described by Leonard Hayflick in the 1960s when he observed that human cells in culture could only divide a finite number of times. But senescence is not just about reaching a division limit. Cells can become senescent in response to DNA damage, oncogene activation, oxidative stress, telomere shortening, or mitochondrial dysfunction. It is a stress response — a way for damaged cells to stop proliferating and avoid becoming cancerous.
The problem is what comes next.
The SASP: A Toxic Cocktail
Senescent cells do not just sit quietly. They secrete a complex mixture of inflammatory cytokines, chemokines, growth factors, and matrix-degrading enzymes collectively known as the senescence-associated secretory phenotype, or SASP. This secretome is not subtle — it actively damages surrounding tissue.
SASP components include interleukin-6 (IL-6), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), matrix metalloproteinases (MMPs), and vascular endothelial growth factor (VEGF), among many others. These molecules drive chronic inflammation, degrade the extracellular matrix, promote fibrosis, and — perhaps most insidiously — induce senescence in neighboring healthy cells through a process called paracrine senescence.
This means senescent cells are contagious. A small number of zombie cells can spread dysfunction throughout a tissue, creating a vicious cycle of damage and senescence that accelerates with age.
The Senolytic Hypothesis
In 2011, researchers at the Mayo Clinic made a landmark discovery. Using a genetic trick in mice engineered to allow selective elimination of senescent cells (the INK-ATTAC model), they showed that clearing p16-positive senescent cells delayed age-related pathology in multiple organs. The treated mice had better kidney function, healthier hearts, and longer healthspans. A follow-up study in 2016 demonstrated that senescent cell clearance extended median lifespan by 25% in naturally aged mice.
These genetic proof-of-concept studies launched a race to find drugs that could accomplish the same thing — molecules that selectively kill senescent cells while sparing healthy ones. These drugs became known as senolytics, from the Latin "senex" (old) and Greek "lysis" (destruction).
Dasatinib + Quercetin: The First Senolytic Cocktail
The first pharmacological senolytics were identified by James Kirkland's group at the Mayo Clinic in 2015. Using a targeted approach, they reasoned that senescent cells depend on pro-survival pathways to resist apoptosis — the same pathways that keep them alive as zombie cells could be their Achilles' heel.
They found that dasatinib, a tyrosine kinase inhibitor approved for cancer treatment, was effective against senescent fat cell progenitors. Quercetin, a natural flavonoid found in fruits and vegetables, was effective against senescent endothelial cells. Together, the combination — known as D+Q — cleared senescent cells across multiple tissue types.
In mice, intermittent D+Q treatment improved cardiovascular function, increased exercise capacity, reduced osteoporosis, and extended healthspan. The treatment did not need to be continuous — periodic "hit and run" dosing was sufficient because senescent cells take weeks to reaccumulate after clearance.
Human trials of D+Q have shown promising early results. A small study in patients with idiopathic pulmonary fibrosis (IPF) demonstrated improved physical function after just three weeks of intermittent dosing. A trial in diabetic kidney disease showed reduced senescent cell burden in adipose tissue. Larger trials are ongoing.
Fisetin: The Natural Senolytic
Fisetin, a flavonoid found in strawberries, apples, and onions, emerged as another promising senolytic from screening studies. In mice, high-dose fisetin reduced senescent cell markers, decreased SASP-related inflammation, and extended both median and maximum lifespan when administered late in life.
The AFFIRM-LITE trial tested fisetin in older adults and generated considerable interest in the longevity community. Fisetin has the advantage of being a natural compound with a favorable safety profile, though its bioavailability is poor and the doses used in animal studies are far higher than what you would get from eating strawberries. Formulation improvements, including lipid nanoparticle delivery, are being explored to improve its pharmacokinetics.
Navitoclax: Potent but Problematic
Navitoclax (ABT-263) is a BCL-2 family inhibitor originally developed as a cancer drug. It is one of the most potent senolytics identified, effectively clearing senescent cells by disabling the anti-apoptotic proteins that keep them alive. In preclinical models, navitoclax rejuvenated the hematopoietic system, improved muscle stem cell function, and reduced atherosclerotic plaque burden.
However, navitoclax has a serious side effect: it causes thrombocytopenia (low platelet counts) because platelets depend on BCL-xL for survival. This has limited its use as a senolytic in healthy aging and pushed researchers toward developing more selective BCL-2 inhibitors or next-generation compounds that spare platelets.
Unity Biotechnology: The Clinical Pioneer
Unity Biotechnology was founded in 2011 specifically to develop senolytic medicines and became the first company to take senolytics into clinical trials. Their initial focus was UBX0101, an MDM2/p53 interaction inhibitor designed to clear senescent cells in osteoarthritic joints via local injection.
The Phase 2 trial of UBX0101 for knee osteoarthritis did not meet its primary endpoint, a significant setback for the field. However, Unity pivoted and developed UBX1325, a BCL-xL inhibitor delivered by intravitreal injection for age-related eye diseases including diabetic macular edema and age-related macular degeneration. Local delivery to the eye avoids the systemic thrombocytopenia seen with navitoclax, and early clinical data has been encouraging.
Unity's journey illustrates both the promise and difficulty of translating senolytic science into approved therapies. The biology is compelling, but finding the right drug, the right delivery route, and the right patient population requires rigorous clinical work.
Gene Therapy Approaches
Some of the most innovative senolytic strategies use gene therapy to selectively destroy senescent cells. These approaches exploit the fact that senescent cells express unique promoters — particularly p16INK4a and p21 — that are largely silent in healthy cells.
By placing a suicide gene or a gene encoding a pro-apoptotic protein under the control of a senescence-specific promoter, researchers can build genetic circuits that activate only in senescent cells. When delivered via adeno-associated virus (AAV) vectors, these constructs can clear senescent cells throughout the body with remarkable specificity.
Oisin Biotechnologies (now part of Amplitude Life Sciences) has been a pioneer in this approach, developing lipid nanoparticle-delivered DNA constructs that express a lethal protein only in cells with active p16 or p53 promoters. In mice, their SENSOlytic platform reduced senescent cell burden and improved multiple measures of healthspan.
Gene therapy senolytics offer a potential advantage over small molecules: exquisite selectivity. While drugs like dasatinib inevitably affect some healthy cells, a genetically encoded senolytic only activates in cells expressing senescence markers. The trade-off is the complexity and cost of gene therapy delivery.
What Comes Next
The senolytic field is maturing rapidly. Several clinical trials targeting different age-related conditions are underway, and the drug pipeline is expanding beyond the original D+Q combination. Second-generation senolytics with better selectivity, fewer side effects, and improved pharmacokinetics are in development.
Key questions remain. Which senescent cell populations are most harmful, and which might be beneficial? How often should senolytics be administered? Are there biomarkers that can identify patients who would benefit most? And can senolytics prevent age-related disease if started early enough, or are they primarily useful once disease is established?
The zombie cell theory of aging has moved from a provocative hypothesis to a therapeutic reality. Whether senolytics will become a routine part of medicine — perhaps taken periodically throughout life to keep the senescent cell burden in check — depends on the results of ongoing and future clinical trials. The science, at least, is firmly on their side.
Sources & Further Reading
- Xu, M. et al. "Senolytics improve physical function and increase lifespan in old age." Nature Medicine 24, 1246–1256 (2018).
- Justice, J.N. et al. "Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study." EBioMedicine 40, 554–563 (2019). — First human senolytic trial.
- Unity Biotechnology Pipeline — UBX1325 for diabetic macular edema.
Last updated: March 2026.
